Table 1.
Baseline characteristics in the 527 patients classified as having a VeriStrat Poor or Good status.
| Characteristics | VeriStrat Poor N = 239 |
VeriStrat Good N = 288 |
P-value for differenceb |
|---|---|---|---|
| Age at entry, median (range) | 76 (51–90) | 78 (51–91) | 0.006 |
| Sex | Number of patients (%) | ||
| Male | 159 (66.5) | 156 (54.2) | 0.004 |
| Female | 80 (33.5) | 132 (45.8) | |
| ECOG performance status | |||
| 0-1 (only 9 ECOG 0) | 32 (13.4) | 57 (19.8) | 0.06 |
| 2 | 133 (55.6) | 162 (56.2) | |
| 3 | 74 (31.0) | 69 (24.0) | |
| Stage | |||
| IIIB | 93 (38.9) | 92 (31.9) | 0.10 |
| IV | 146 (61.1) | 196 (68.1) | |
| Histology | |||
| Adenocarcinoma | 66 (27.6) | 129 (44.8) | <0.001 |
| Squamous | 121 (50.6) | 93 (32.3) | |
| Other | 52 (21.8) | 66 (22.9) | |
| Smoking status | |||
| Current smoker | 89 (37.2) | 100 (34.7) | 0.14 |
| Former smoker | 142 (59.4) | 167 (58.0) | |
| Never smoked | 8 (3.4) | 21 (7.3) | |
| Known EGFR status | n = 144 | n = 166 | 0.006 |
| Mutant positive | 6 (4.2) | 21 (12.6) | |
| Wild-type | 138 (95.8) | 145 (87.4) | |
| Trial treatment | 0.04 | ||
| Erlotinib | 115 (48.1) | 164 (56.9) | |
| Placebo | 124 (51.9) | 124 (43.1) | |
| Rash statusa | n = 197 | n = 267 | 0.12 |
| Placebo | 103 (52.3) | 114 (42.7) | |
| No rash (erlotinib) | 39 (19.8) | 65 (24.3) | |
| Rash (erlotinib) | 55 (27.9) | 88 (33.0) | |
ECOG, Eastern Cooperative Oncology Group; EGFR, epidermal growth factor receptor.
a
First-cycle rash in the erlotinib group (among patients who started treatment and alive at 28 days).
b
P-value for the difference between VeriStrat Poor and Good.